Which manufacturer produces bedaquiline?

Bedaquiline (Bedaquiline) is a new anti-tuberculosis drug used to treat multidrug-resistant tuberculosis (MDR-TB). It is developed and produced by Janssen Pharmaceuticals. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, focuses on the development and production of innovative drugs. Bedaquiline was approved by the U.S. Food and Drug Administration (FDA) in 2012, becoming the first new drug approved for tuberculosis in more than 40 years.

Bedaquiline blocks the proton pump of mycobacteriaATP synthase. It is the first member of the diarylquinoline class of drugs. Bedaquiline has bactericidal properties. ATP production is necessary for cellular energy production, and its loss results in inhibition of mycobacterial growth within hours of addition of bedaquiline. Bedaquiline-induced mycobacterial cell death does not occur until several days after treatment but death continues thereafter. This mechanism of action allows bedaquiline to exhibit good efficacy in traditional anti-tuberculosis therapy, especially when targeting drug-resistant tuberculosis strains, showing great potential.

When using bedaquiline, patients typically receive a 24-week treatment regimen. Some side effects may occur during treatment, such as nausea, headache, and abnormal liver function, so the patient's health needs to be monitored regularly when using this drug. In addition, because the use of bedaquiline involves the complexities of anti-tuberculosis treatment, physicians need to carefully evaluate the patient's specific situation, including the type of drug resistance and overall health status, when prescribing.

The promotion and use of bedaquiline around the world has also received widespread attention, especially in countries and regions where tuberculosis is endemic. Since the treatment of multidrug-resistant tuberculosis is costly, long-term, and has limited efficacy, the emergence of bedaquiline has brought new hope to this field.